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Abstract
Background: Inflammation is more common among African Americans (AAs), and it is associated with frailty, poor
physical performance, and mortality in community-dwelling older adults. Given the elevated inflammation levels
among end-stage renal disease (ESRD) patients, inflammation may be associated with adverse health outcomes
such as frailty, physical impairment, and poor health-related quality of life (HRQOL), and these associations may
differ between AA and non-AA ESRD patients.
Methods: One thousand three ESRD participants were recruited at kidney transplant evaluation (4/2014–5/2017),
and inflammatory markers (interleukin-6 [IL-6], tumor necrosis factor-a receptor-1 [TNFR1], C-reactive protein [CRP])
were measured. We quantified the association with frailty (Fried phenotype), physical impairment (Short Physical
Performance Battery [SPPB]), and fair/poor HRQOL at evaluation using adjusted modified Poisson regression and
tested whether these associations differed by race (AA vs. non-AA).
Results: Non-AAs had lower levels of TNFR1 (9.7 ng/ml vs 14.0 ng/ml, p < 0.001) and inflammatory index (6.7 vs 6.8,
p < 0.001) compared to AAs, but similar levels of IL-6 (4.5 pg/ml vs 4.3 pg/ml, p > 0.9) and CRP (4.7 μg/ml vs 4.9 μg/ml,
p = 0.4). Non-AAs had an increased risk of frailty with elevated IL-6 (RR = 1.58, 95% CI:1.27–1.96, p < 0.001), TNFR1
(RR = 1.60, 95% CI:1.25–2.05, p < 0.001), CRP (RR = 1.41, 95% CI:1.10–1.82, p < 0.01), and inflammatory index (RR = 1.82,
95% CI:1.44–2.31, p < 0.001). The associations between elevated inflammatory markers and frailty were not present
among AAs. Similar results were seen with SPPB impairment and poor/fair HRQOL.
Conclusions: Non-AAs with elevated inflammatory markers may need closer follow-up and may benefit from
prehabilitation to improve physical function, reduce frailty burden, and improve quality of life prior to transplant.
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Background
ESRD patients experience accelerated aging resulting in
adverse health outcomes of aging such as frailty, lower
extremity impairment, and poor health-related quality of
life (HRQOL) [1–5]. More specifically, frailty, a syn-
drome of decreased physiologic reserve [6], is present in
41.8% of hemodialysis patients [2, 3, 7] and is associated
with falls [2], hospitalizations [1, 7, 8], poor cognitive
function [3], decreased HRQOL [4], and mortality [1, 7].
Lower extremity impairment, measured using the Short
Physical Performance Battery (SPPB) [9], is an important
predictor of mortality in ESRD patients undergoing KT
and is associated with longer length of stay after KT [5].
Additionally, poor HRQOL is associated with frailty
[4, 10] and predicts cardiovascular health and physical
performance in ESRD patients [11].
In community dwelling older adults, elevated
inflammatory markers including interleukin 6 (IL-6),
C-reactive protein (CRP), and tumor necrosis factor-α
receptor-1 (TNFR1) are associated with higher risk of
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multiple adverse health outcomes of aging including
frailty [12], disability [13], and decreased grip strength
[14]; furthermore, these adverse health outcomes of
aging are important risk factors for mortality [15, 16].
Additionally, chronic dialysis is associated increased in-
flammation [17], and inflammation is a risk factor for
mortality in ESRD patients [18, 19]. Among patients
undergoing hemodialysis, there is a differential impact of
inflammatory markers on mortality by race [20, 21].
Therefore, it is likely that the association between in-
flammatory marker levels and adverse health outcomes
of aging also differ by race.
Quantifying the association between inflammatory
markers and adverse health outcomes of aging such as
frailty, lower extremity impairment, and poor HRQOL
may provide insight into the role of aging biology to
explain racial disparities related to poor outcomes for
ESRD patients. Thus, the goals of this study were to: 1)
quantify the association between inflammation and ad-
verse health outcomes of aging (frailty, lower extremity
function, and poor HRQOL) and 2) test whether there
are differential associations between elevated inflamma-
tory markers and adverse health outcomes of aging by




This was a cross-sectional cohort study of 1003
English-speaking ESRD consecutive participants 18 years
or older who were evaluated for KT at the Johns Hopkins
Hospital, Baltimore, Maryland, from April 2014 to May
2017 (N = 891) and the University of Michigan, Ann
Arbor, Michigan, from July 2015 to March 2016 (N = 112).
Participants were eligible for enrollment if they were
English speaking and aged 18 or older; the refusal rate
during the enrollment period was 18%. At the time of KT
evaluation, we measured Fried frailty, SPPB, HRQOL, and
obtained a blood sample as described below. Additional
participant characteristics were also assessed at KT evalu-
ation or abstracted from the transplant evaluation medical
record (age, sex, race, time on dialysis, type of dialysis,
Charlson comorbidity index [CCI]). Race was measured
using self-reported data from the electronic health record,
EPIC. Participants selected among Black/African
American (AA), White/Caucasian, Asian, Native
Hawaiian, or Other. Participants who were not on dialysis
at time of KT evaluation were classified as pre-emptive
transplant. Comorbidities were classified as present if the
participant currently suffered from the disease or had a
previous history the disease. The Johns Hopkins Institu-
tional Review Board and the University of Michigan
Institutional Review Board approved the study and partici-
pants provided written informed consent.
Frailty
We studied the physical frailty phenotype defined
and validated by in community-dwelling older adults
[6, 10, 22–30] and by our research group in ESRD
and KT populations [2–5, 7, 8, 31–38]. Frailty was
defined as a score of three or more of the Fried
frailty components: shrinking (self-report of uninten-
tional weight loss of more than 10 pounds in the
past year based on dry weight); weakness (grip--
strength below an established cutoff based on gender
and BMI); exhaustion (self-report); low activity
(Kcals/week below an established cutoff ); and slowed
walking speed (walking time of 15 ft below an estab-
lished cutoff by gender and height) [6]. Each of the 5
components was scored as 0 (absence) or 1 (pres-
ence). The aggregate frailty score was calculated as
the sum of the component scores (range 0–5). Nonf-
rail was defined as a score of 0 and frail was defined
as a score of ≥3.
Short physical performance battery (SPPB)
The SPPB is an objective test of lower extremity func-
tion (balance, walking speed, repeated chair stands) [9].
Each component has a score ranging from 0 to 4, for a
summed composite score ranging from 0 to 12. SPPB
impairment was defined as having a SPPB score < 10 on
a scale 0 to 12 [5, 9]. The test is administered by trained
research assistants and takes approximately 5 min to
complete. For the balance portion, recipients are asked
to stand and remain in several progressively more
difficult positions (side-by-side, semi-tandem, and
full-tandem stances) for 10 s each. For the walking speed
test, recipients’ walking speed is measured as they are
asked to walk 15-ft at a normal pace. Finally, for the
chair stand portion, recipients are asked to fold their
arms across their chest and rise from a chair five times
as quickly as possible. A full description of administra-
tion and scoring has been detailed elsewhere [9].
Health related quality of life (HRQOL)
HRQOL was measured using a single question instru-
ment for global subjective health from the kidney disease
quality of life assessment: “In general, would you say
your health is …”. Participants reported HRQOL as
being “Excellent”, “Very Good”, “Good”, “Fair” or “Poor”
during KT evaluation. These classifications have been
used in previous populations of ESRD patients and KT
recipients [4, 37].
Measures of inflammation
Serum inflammatory markers, IL-6, TNFR1, and CRP,
were collected at KT evaluation, as these markers are
frequently elevated in frailty and end-stage renal disease
[38]. The blood samples were collected after evaluation
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in kidney transplant clinic at the same time as routine
kidney transplant lab testing for all participants. There
were no differences in sample volume (10 mL) between
hemodialysis and non-hemodialysis participants. A full
description of inflammation measurements performed
by our research group has been detailed elsewhere [38].
We calculated the inflammatory index score using IL-6
and TNFR1 as has been previously published: [1/3 x
log(IL-6)] + [2/3 x log(TNFR1)] [16]. Elevated inflam-
mation markers were defined as >1SD higher level of
IL-6, TNFR1, CRP or inflammation index on the log
scale [38].
Adverse health outcomes of aging and inflammation
Modified Poisson regression was used to estimate the as-
sociation between inflammatory markers (IL-6, TNFR1,
CRP, and inflammatory index) and adverse health out-
comes of aging (frailty, SPPB impairment, and poor
HRQOL). Elevated inflammation markers were defined
as >1SD higher level of IL-6, TNFR1, CRP or inflamma-
tion index on the log scale. For each change in 1SD,
there was an association between inflammation an ad-
verse health outcome of aging. These models were strati-
fied by race (AA and non-AA) and adjusted for age, sex,
CCI, type of dialysis (hemodialysis, peritoneal dialysis,
and no dialysis), and time on dialysis. We also used
modified Poisson regression with a Wald test to estimate
the interaction between non-AA and AA for each
inflammatory marker with adjustment for the same
confounders above.
Statistical analysis
Continuous variables were compared using t-tests and
categorical variables were compared using χ2 tests. For
all analyses, a P value < 0.05 was considered significant.




Among 1003 KT evaluation participants, the mean age
was 55 (SD = 13), 40.0% were female, 41.3% were AA,
53.0% were on hemodialysis, and 34.4% were evaluated
for pre-emptive KT (Table 1). The mean CCI score was
2.0 (SD = 2.4) (Table 1). AA KT candidates were more
likely to be younger (mean age at evaluation: 53 years vs.
56 years, p < 0.001), have diabetes (49.2% vs. 40.7%, p =
0.008), and be HIV+ (8.7% vs. 0.9%, p < 0.001) (Table 1).
The mean CCI score (2.1 vs. 2.0, p = 0.50) was similar
between AAs and non-AAs. AAs were more likely to be
on hemodialysis (61.9% vs. 45.1%, p < 0.001) and more
likely to be on dialysis for more than 2 years (32.4% vs.
19.4%, p < 0.001), but less likely to evaluated for
pre-emptive transplant (26.2% vs. 43.2%, p < 0.001).







n = 589, 58.7% n = 414, 41.3%
Age, yearsa 56.2 (13.4) 52.9 (12.9) < 0.001
Female, % 36.0 38.4 0.44
Charlson comorbidity indexa 2.0 (2.5) 2.1 (2.2) 0.50
Comorbidities, %
Myocardial infarction 12.1 9.9 0.28
Peripheral vascular disease 9.0 6.0 0.09
Cerebral vascular disease 8.0 9.0 0.59
Dementia 0.9 0.7 0.83
Chronic lung disease 4.5 3.4 0.41
Rheumatologic disease 5.5 8.1 0.10
Peptic ulcer disease 3.8 2.2 0.16







Metastatic cancer 0.9 0.7 0.82
Leukemia 0.9 0.2 0.22
Lymphoma 1.2 0.5 0.24
Congestive heart failure 14.3 14.3 1.00
HIV+ 0.9 8.7 < 0.001
Dialysis type < 0.001
No dialysis 43.2 26.2
Hemodialysis 45.1 61.9
Peritoneal dialysis 11.8 11.9
Time on dialysis < 0.001
0 year 48.2 29.0
1 or 2 years 32.4 38.6
More than 2 years 19.4 32.4
Inflammatory Markerb
IL-6, pg/ml 4.5 [2.8–8.4] 4.3 [2.8–8.1] 0.95
TNFR1, ng/ml 9.7 [5.8–17.7] 14.0 [7.8–20.5] < 0.001
CRP, ug/ml 4.7 [1.9–10.2] 4.9 [2.2–11.0] 0.36
Inflammatory Index 6.7 [6.2–7.1] 6.8 [6.5–7.2] < 0.001
Frail status, % 0.01
Nonfrail 55.2 48.3
Intermediate Frail 28.7 28.3
Frail 16.1 23.4
SPPB impairment, % 36.3 46.0 0.003
Fair/Poor HRQOL, % 48.0 50.9 0.37
amean (standard deviation)
bmedian [IQR]
SPPB Short Physical Performance Battery, HRQOL Health Related Quality
of Life, IL-6 Interleukin-6, TNFR1 tumor necrosis factor-α receptor-1,
CRP C-reactive protein
The aggregate inflammatory index consists of IL-6 and TNFR1
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Race and inflammatory markers
AAs had higher TNFR1 levels (median [IQR]: 14.0
[7.8–20.5] ng/ml vs. 9.7 [5.8–17.7] ng/ml, p < 0.001)
and inflammatory index scores (6.8 [6.5–7.2] vs. 6.7
[6.2–7.1], p < 0.001) compared to non-AAs (Table 1)
(Fig. 1a, d). However, AAs had similar IL-6 (4.3 [2.8–8.1]
pg/ml vs. 4.5 [2.8–8.4] pg/ml, p = 0.95) and CRP (4.9 [2.2–
11.0] ug/ml vs. 4.7 [1.9–10.2] ug/ml, p = 0.36) levels
compared to non-AAs (Table 1, Fig. 1b, c).
Race and adverse health outcomes of aging
At the time of evaluation, 19.1% of KT candidates were
frail, 40.0% had SPPB impairment, and 49.2% reported
poor HRQOL. Additionally, AAs were more likely to be
frail (23.4% vs. 16.1%, p = 0.01) and have SPPB impair-
ment (46.0% vs. 36.3%, p = 0.003) compared to non-AAs,
but the prevalence of poor HRQOL was similar between
AAs and non-AAs (50.9% vs. 48.0%, p = 0.37) (Table 1).
Frailty, inflammation, and race
The risk of frailty associated with elevated IL-6 varied by
participant race (interaction p = 0.04): Elevated IL-6 was
associated with a 1.58-fold (95% CI: 1.27–1.96, p < 0.001)
increased risk of frailty among non-AAs but did not in-
crease the risk of frailty among AAs (aRR: 1.18, 95% CI:
0.99–1.42, p = 0.06) (Table 2). The risk of frailty associ-
ated with elevated TNFR1 also varied by participant race
(interaction p = 0.02): Elevated TNFR1 was associated
with a 1.60-fold (95% CI: 1.25–2.05, p < 0.001) increased
risk of frailty among non-AAs, but it was not associated
with an increased risk of frailty among AAs (aRR: 1.18,
95% CI: 0.92–1.51, p = 0.2). The risk of frailty by elevated
CRP did not vary by participant race (interaction p =
0.1): Elevated CRP was associated with a 1.41-fold (95%
CI: 1.10–1.82, p < 0.01) increased risk of frailty among
non-AAs but not among AAs (aRR: 1.11, 95% CI: 0.92–
1.33, p = 0.3). The risk of frailty associated with elevated
inflammatory index varied by participant race (inter-
action p < 0.001): Elevated inflammatory index was asso-
ciated with a 1.82-fold (95% CI: 1.44–2.31, p < 0.001)
increased risk of frailty among non-AAs and a 1.26-fold
(95% CI: 1.02–1.56, p = 0.03) increased risk of frailty
among AAs (Table 2).
SPPB impairment, inflammation, and race
The risk of SPPB impairment associated with elevated
IL-6 varied by participant race (interaction p < 0.01): Ele-
vated IL-6 was associated with a 1.49-fold (95%CI: 1.33–
1.67, p < 0.001) increased risk of SPPB impairment
among non-AAs and a 1.20-fold (95%CI: 1.08–1.32, p =
0.001) increased risk of SPPB impairment among AAs
(Table 2). The risk of SPPB impairment associated with
elevated TNFR1 also varied by participant race (inter-
action p < 0.01): Elevated TNFR1 was associated with a
1.47-fold (95% CI: 1.27–1.71, p < 0.001) increased risk of
SPPB impairment among non-AAs and a 1.17-fold (95%
CI: 1.01–1.36, p = 0.04) increased risk of SPPB impair-
ment among AAs. The risk of SPPB impairment associ-
ated with elevated CRP did not vary by participant race
(interaction p = 0.09): Elevated CRP was associated with
an increased risk of SPPB impairment in non-AAs (aRR:
1.32, 95% CI: 1.16–1.49, p < 0.001) and AAs (aRR: 1.14,
95% CI: 1.02–1.27, p = 0.02). The risk of SPPB impair-
ment associated with elevated inflammatory index varied
by participant race (interaction p < 0.001): Elevated in-
flammatory index was associated with a 1.67-fold
(95%CI: 1.48–1.90, p < 0.001) increased risk of SPPB im-
pairment among non-AAs and a 1.28-fold (95%CI: 1.13–
1.46, p < 0.001) increased risk of SPPB impairment
among AAs (interaction p < 0.001) (Table 2).
Fair/poor HRQOL, inflammation, and race
The risk of fair/poor HRQOL and elevated IL-6 varied by
participant race (interaction p < 0.001): Elevated IL-6 was
associated with a 1.19-fold (95% CI: 1.09–1.29, p < 0.001)
increased risk of fair/poor HRQOL among non-AAs, but
it was not associated an increased risk of fair/poor
HRQOL among AAs (aRR: 0.96, 95% CI: 0.87–1.06,
p = 0.4) (Table 2). The risk of having fair/poor
HRQOL and elevated TNFR1 varied by participant
race (interaction p < 0.01): Elevated TNFR1 was not
associated with an increased risk of fair/poor
HRQOL among non-AAs (aRR: 1.06, 95% CI: 0.95–
1.19, p = 0.3) and AAs (aRR: 0.88, 95% CI: 0.78–1.00,
p = 0.05). The risk of Fair/Poor HRQOL and elevated
CRP varied by participant race (interaction p < 0.01):
Elevated CRP was associated with a 1.18-fold (95%
CI: 1.08–1.30, p < 0.001) increased risk of fair/poor
HRQOL among non-AAs but was not associated
with an increased risk of fair/poor HRQOL among
AAs (aRR: 0.99, 95% CI: 0.91–1.09, p = 0.9). The risk
of fair/poor HRQOL and elevated inflammatory index var-
ied by participant race (interaction p < 0.001): Elevated in-
flammatory index was associated with a 1.16-fold (95% CI:
1.05–1.29, p < 0.01) increased risk of having fair/poor
HRQOL among non-AAs, but it was not associated
with an increased risk of fair/poor HRQOL among AAs
(aRR: 0.92, 95% CI: 0.82–1.03, p = 0.1) (Table 2).
Discussion
Using a two-center prospective cohort of 1003 ESRD
participants evaluated for KT, we found that AAs had
higher levels of TNFR1 (p < 0.001) and inflammatory
index (p < 0.001) compared to non-AAs, and we
found that AAs and non-AAs had similar levels of
IL-6 (p > 0.9) and CRP (p = 0.4). Despite higher levels
of some inflammatory markers in AAs, non-AAs had
a higher risk of adverse health outcomes of aging,
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including frailty, SPPB impairment, and fair/poor
HRQOL compared to AAs. In non-AAs elevation of
all inflammatory markers (IL-6, TNFR1, CRP, and in-
flammatory index) were independently associated with
an increased risk of frailty and SPPB impairment after
accounting for potential confounders. Elevated inflam-
matory markers (IL-6, CRP, and inflammatory index)
were associated with an increased risk of fair/poor
HRQOL in non-AA KT candidates. Among AA KT
candidates, elevated inflammatory markers (IL-6,
TNFR1, CRP, and inflammatory index) were associ-
ated with an increased risk of SPPB impairment, and
an elevated inflammatory index was associated with
an increased risk of frailty. However, elevated inflam-
matory markers were not associated with an increased
risk of having fair/poor HRQOL in AA candidates.
Our findings of higher levels of inflammatory markers
among AAs compared to non-AAs are consistent with
studies in community-dwelling adult populations [39,
40]. In the multi-ethnic population of the Dallas Heart
Study, black subjects had higher CRP levels than white
subjects [39], and as part of the Adventist Health
Study-2, blacks had higher levels of CRP and IL6 com-
pared to whites, yet no difference in TNFR1 levels. [40]
Notably, we extend these community-dwelling studies of
older adults (mean age 64–71) to ESRD patients across
all ages and show that AAs have higher levels of TNFR1
and inflammatory index. The chronologic age of ESRD
patients is likely not reflective of the true physiologic
reserve you would see in community-dwelling patients
of the same age. Thus, findings seen in older
community-dwelling older adults are often seen in youn-
ger end-stage renal disease patients. We feel that ESRD
does play a significant role in the accelerated aging
process and puts these patients at increased risk of ad-
verse health outcomes of aging.
Previous studies have shown greater survival of AAs
on dialysis at higher levels of CRP [20] and IL-6 [21]
which is consistent with our findings on the associ-
ation between lower risk of adverse health outcomes
and elevated inflammation in AAs compared to
non-AAs. While inflammation, marked by elevated
CRP and IL-6 levels, has been previously associated
with frailty [11] and poorer physical function in older
adults [15] our study extended these findings into a
population of KT candidates, encompassing all ages.
Our research builds on these previous findings and
shows that elevated inflammation is an important
Fig. 1 Distribution of inflammatory markers [(a) IL-6 (p > 0.9), (b) TNFR1
(p < 0.001), (c) CRP (p = 0.4), (d) inflammation index (p < 0.001)] by race
(Non-African American vs. African American) among 1003 end-stage
renal disease participants. The inflammatory index score was calculated
using IL-6 and TNFR1: [1/3 x log(IL-6)] + [2/3 x log(TNFR1)]
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measure to identify the risk of specific adverse health
outcomes of aging such as frailty, SPPB impairment,
and fair/poor HRQOL, all of which have been previ-
ously associated with poor outcomes including death
and disability. Furthermore, we have shown that the
impact of inflammation on adverse health outcomes
of aging in KT candidates may be somewhat mitigated
in AAs, and comorbidities in AAs may confound the
association of inflammation and adverse health
outcomes of aging. These findings are important to
consider in the clinical practice and evaluation of
end-stage renal disease patients showing that elevated
inflammatory levels may lead to adverse outcomes in
non-AAs and comorbidities in AAs may lead to more
adverse outcomes rather than elevated inflammatory
levels alone. Clinicians should consider measurement
of inflammatory markers in addition traditional
comorbidity assessment to identify who may benefit
from prehabilitation or exercise training to prevent
subsequent adverse health outcomes of aging [41].
This study has several important strengths, including a
large sample size from two different hospitals, the meas-
urement of the novel gerontology factor of frailty, lower
extremity impairment, and fair/poor HRQOL (rather
than the use of proxies), and the analysis of 3 inflamma-
tory markers collected at the time of KT evaluation.
Additionally, to preserve stored samples, we only ana-
lyzed the most recent serum samples (from 4/2014);
those with and without analyzed blood samples only
differed on smoking status. The blood draw included in
this study was a cross-sectional representation on one
day, so variability in inflammatory markers may be
missed due to dialysis, infections, medications, or
hospitalizations. This study has several limitations worth
noting. This study is a cross-sectional analysis of inflam-
matory markers and adverse health outcomes of aging,
Table 2 Association between inflammatory markers and adverse health outcomes of aging (frailty, SPPB impairment, and poor
HRQOL) by race
Outcome Inflammatory Marker Race RR (95% CI) Interaction p value aRR (95% CI) Interaction p value
Frailty IL-6 Non-AA 1.63 (1.36, 1.94) 0.05 1.58 (1.27, 1.96) 0.04
AA 1.27 (1.08, 1.51) 1.18 (0.99, 1.41)
TNFR1 Non-AA 1.39 (1.19, 1.62) 0.02 1.60 (1.25, 2.05) 0.02
AA 1.04 (0.87, 1.25) 1.18 (0.92, 1.51)
CRP Non-AA 1.44 (1.15, 1.81) 0.08 1.41 (1.10, 1.82) 0.1
AA 1.11 (0.91, 1.37) 1.11 (0.92, 1.33)
Inf. Index Non-AA 1.60 (1.35, 1.89) 0.01 1.82 (1.44, 2.31) < 0.01
AA 1.17 (0.97, 1.40) 1.26 (1.02, 1.56)
SPPB impairment IL-6 Non-AA 1.56 (1.41, 1.72) 0.01 1.49 (1.33, 1.67) < 0.01
AA 1.28 (1.15, 1.42) 1.20 (1.08, 1.32)
TNFR1 Non-AA 1.26 (1.14, 1.40) 0.03 1.47 (1.27, 1.71) < 0.01
AA 1.07 (0.95, 1.20) 1.17 (1.01, 1.36)
CRP Non-AA 1.35 (1.21, 1.53) 0.03 1.32 (1.16, 1.49) 0.09
AA 1.13 (1.01, 1.27) 1.14 (1.02, 1.27)
Inf. Index Non-AA 1.45 (1.31, 1.61) 0.01 1.67 (1.48, 1.90) < 0.001
AA 1.19 (1.06, 1.34) 1.28 (1.13, 1.46)
Fair/Poor HRQOL IL-6 Non-AA 1.16 (1.07, 1.27) 0.01 1.19 (1.09, 1.29) < 0.001
AA 0.99 (0.89, 1.09) 0.96 (0.87, 1.06)
TNFR1 Non-AA 1.02 (0.94, 1.11) < 0.01 1.06 (0.95, 1.19) < 0.01
AA 0.84 (0.77, 0.93) 0.88 (0.78, 1.00)
CRP Non-AA 1.16 (1.06, 1.27) 0.01 1.18 (1.08, 1.30) < 0.01
AA 0.98 (0.89, 1.07) 0.99 (0.91, 1.09)
Inf. Index Non-AA 1.09 (1.00, 1.18) 0.001 1.16 (1.05, 1.29) < 0.001
AA 0.87 (0.78, 0.96) 0.92 (0.82, 1.03)
Modified Poisson regression models were adjusted for age, sex, CCI, dialysis type, and time on dialysis/dialysis vintage. Interaction p value marks the difference
between Non-African American (non-AA) and African American (AA) participants
SPPB Short Physical Performance Battery, HRQOL Health Related Quality of Life, IL-6 Interleukin-6, TNFR1 tumor necrosis factor-α receptor-1, CRP C-reactive protein,
aRR adjusted relative risk RR: relative risk
The aggregate inflammatory index consists of IL-6 and TNFR1
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so it is difficult to conclude a causal relationship be-
tween the exposure and outcome; unmeasured
confounding is inherent in any observational study and
may lead to inappropriate inferences. Additionally, we
do not have information on the type of hemodialysis
access (arteriovenous fistula, graft, or catheter) or the
timing of lab draws relative to dialysis.
Conclusions
We have shown that elevated inflammatory markers are
associated with an increased risk of frailty, lower extrem-
ity impairment, and poor HRQOL among non-AAs with
ESRD. While AAs experience an increased risk of frailty
and lower extremity impairment with elevated inflam-
matory markers, non-AAs with elevated inflammatory
markers had a higher risk of these adverse health
outcomes of aging than non-AAs. This quantification
provides early epidemiological evidence that the inflam-
matory pathway may be a novel and important target for
reducing frailty burden and improving physical perform-
ance among KT candidates of all ages, especially among
non-AAs. These findings highlight easy to measure
markers of increased frailty, lower extremity impairment,
and poor HRQOL risk and suggest that inflammatory
markers should be measured during the evaluation
process in order to identify individuals who may benefit
from exercise training intervention or prehabilitation to
improve their physical performance and lower their
frailty burden while waiting for KT.
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